Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • Neo-X-PrimeTM
      • ALG.APV-527
      • ATOR-1017
      • Research projects
    • Scientific publications
    • Technology platform
      • Alligator-GOLD®
      • Alligator-FABTM
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q2 2023
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • News
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. Yearend
Key downloads
Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business updateAlligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business updateAlligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022Interim report January–March 2022
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2023-02-10

Alligator Bioscience AB reports full year financial results for 2022 and for Q4 2022 and provides a business update

Interim results from mitazalimab OPTIMIZE-1 Phase 2 trial in pancreatic cancer exceed 50% Objective Response Rate, the trial passes pre-plan ...
Continue reading
2022-02-112022-05-17
Regulatory

Alligator Bioscience AB: Year End report January–December 2021

OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...
Continue reading
2021-02-26
Regulatory

Alligator Bioscience AB: Year-end Report January-December 2020

Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...
Continue reading
2020-02-12
Regulatory

Alligator Bioscience AB Year-end Report January-December 2019

"2019 was the year when Alligator entered the clinical phase on a broad front. At the beginning of the year, we had one clinical project ...
Continue reading
2019-02-14
Regulatory

Alligator Bioscience AB Year-end Report 2018

The bispecific drug candidate ATOR-1015 in clinical development Significant events October-December• The Swedish MPA (Medical Products Agenc ...
Continue reading
2018-02-16
Regulatory

Alligator Bioscience AB Full Year Report 2017

The Janssen collaboration continues, milestone payment of 6 MUSD triggered Significant events, October-December • Alligator Bioscience recor ...
Continue reading
2017-02-17
Regulatory

Alligator Bioscience AB Full Year 2016 Report

Summary During the quarter were the company’s shares listed for trading on Nasdaq Stockholm Mid Cap. In connection with this were new shares ...
Continue reading
  1. Startpage
  2. News
  3. Yearend
About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
Contact us

Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2019 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all